Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Condition:   Rhinitis, Allergic, Seasonal
Interventions:   Biological: MK-3641;   Biological: Placebo;   Drug: Self-injectable epinephrine;   Drug: Albuterol/Salbutamol;   Drug: Loratadine;   Drug: Olopatadine;   Drug: Mometasone furoate monohydrate
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting – verified June 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.